Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jun 16, 2011

Premium

Title: Method for Treating Cancer Using Anti-Wnt2 Monoclonal Antibodies and siRNA

Patent Number: 7,959,923

Filed: Jan. 30, 2009

Lead Inventor: Liang You, University of California, Oakland

“This invention relates to methods of inhibiting the growth of cells, in particular cancer cells, that over-express Wnt2,” the patent's abstract states. “The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein [and] interferes with Wnt2 signaling or inhibits binding of the Wnt2 protein to another protein, such as a Frizzled receptor.”


Title: Methods and Compositions Involving miRNA and miRNA Inhibitor Molecules

Patent Number: 7,960,359

Filed: Aug. 10, 2007

Lead Inventor: David Brown, Asuragen

The invention, the patent's abstract states, “concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the ... invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.”


Title: Method of Designing siRNAs for Gene Silencing

Patent Number: 7,962,316

Filed: Oct. 27, 2004

Lead Inventor: Aimee Jackson, Rosetta Inpharmatics (Merck)

The invention provides “a method for identifying siRNA target motifs in a transcript using a position-specific score matrix approach,” the patent's abstract states. “The invention also provides a method for identifying off-target genes of an siRNA using a position-specific score matrix approach. The invention further provides a method for designing siRNAs with higher silencing efficacy and specificity … [as well as] a library of siRNAs comprising siRNAs with high silencing efficacy and specificity.”


Title: RNAi-Related Inhibition of TNFa Signaling Pathway for Treatment of Glaucoma

Application Number: 20110135579

Filed: Feb. 20, 2011

Lead Inventor: Jon Chatterton, Alcon

“RNA interference is provided for inhibition of tumor necrosis factor-alpha by silencing TNF-alpha cell-surface receptor TNF receptor-1 mRNA expression, or by silencing TNF-alpha-converting enzyme mRNA expression,” the patent application's abstract states. “Silencing such TNF-alpha targets, in particular, is useful for treating patients having a TNF-alpha-related condition or at risk of developing a TNF-alpha-related condition such as the ocular conditions associated with elevated intraocular pressure, including glaucoma and ocular hypertension.”


Title: Nucleic Acid Compounds for Inhibiting PLK1 Gene Expression and Uses Thereof

Application Number: 20110136233

Filed: Aug. 5, 2009

Lead Inventor: Steven Quay, MDRNA (Marina Biotech)

The invention, the patent application's abstract states, comprises: RNA molecules, for example, meroduplex ribonucleic acid molecules, capable of decreasing or silencing expression of the PLK1 gene. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a PLK1 mRNA. Also provided are methods of decreasing expression of a PLK1 gene in a cell or in a subject to treat a PLK family member-related disease.”


Title: Treatment of Fibrotic Conditions

Application Number: 20110136890

Filed: Dec. 22, 2008

Lead Inventor: David Lawrence Becker

The patent application, its abstract states, claims the “treatment of fibrosis and fibrotic diseases, disorders, and conditions, and associated methods, compositions, formulations, and articles.”

The application specifically claims RNAi oligos targeting connexin 43.


Title: Nucleic Acid Molecules and Collections Thereof, Their Application and Identification

Application Number: 20110136891

Filed: Dec. 23, 2010

Lead Inventor: Ronald Plasterk, Royal Netherlands Academy of Arts and Sciences

The invention, the patent application's abstract states, comprises “a method for characterizing a sample comprising nucleic acid derived from a cell. The method comprises determining whether a sample comprises at least a minimal sequence of at least one new microRNA ... or a mammalian ortholog thereof, and characterizing the sample on the basis of the presence or absence of the miRNA. The invention further provides new nucleic acid molecules and collections thereof and their use in therapeutic and diagnostic applications. The invention furthermore provides a method for identifying a miRNA molecule or a precursor molecule thereof.”


Title: Oligonucleotide-, Protein-, and/or Peptide-Polymer Conjugates

Application Number: 20110136893

Filed: Dec. 21, 2007

Lead Inventor: Karl-Hermann Schlingensiepen, Antisense Pharma

The invention, the patent application's abstract states, relates to “a conjugate or compound comprising polyethyleneglycol and an oligonucleotide, wherein at least one polyethyleneglycol is linked to the 5'-end of the oligonucleotide and at least one polyethyleneglycol is linked to the 3'-end of the oligonucleotide, [wherein] the molecular weight of the polyethyleneglycol linked to the 5'- and 3'-end of the oligonucleotide is identical and is [less than] 5,000 [daltons], or wherein the molecular weight of the polyethyleneglycol linked to the 5'- and 3'-end of the oligonucleotide is different.”

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.